Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder

Cancer Science

Volumn 100, Issue 5, 2009, Pages 896-902

  Luo, Jun Hang ^a,b   Hua, Wen Feng ^a   Rao, Hui Lan ^a   Liao, Yi Ji ^a   Kung, Hsiang Fu ^a   Zeng, Yi Xin ^a   Guan, Xin Yuan ^a,c   Chen, Wei ^a,b   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 5A; INITIATION FACTOR 5A2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR RECURRENCE; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE INITIATION FACTORS; RECURRENCE; RNA, MESSENGER; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 65349085547     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01126.x     Document Type: Article

References (32)

1. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-80.
2. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-6.
3. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of UC. Nat Clin Pract Urol 2006; 3: 327-40.
4. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008; 99: 646-52.
5. Veltman JA, Fridlyand J, Pejavar S et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872-80.
6. Koo SH, Kwon KC, Ihm CH et al. Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet Cytogenet 1999; 110: 87-93.
7. Terracciano L, Richter J, Tornillo L et al. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999; 189: 230-5.
8. Simon R, Burger H, Semjonow A et al. Patterns of chromosomal imbalances in muscle invasive UC. Int J Oncol 2000; 17: 1025-9.
9. Sham JS, Tang TC, Fang Y et al. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet 2002; 133: 39-44.
10. Kettunen E, el-Rifai W, Bjorkqvist AM et al. A broad amplification pattern at 3q in squamous cell lung cancer - A fluorescence in situ hybridization study. Cancer Genet Cytogenet 2000; 117: 66-70.
11. He QJ, Zeng WF, Sham JS et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet 2003; 144: 112-8.
12. Pack SD, Karkera JD, Zhuang Z et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 1999; 25: 160-8.
13. Guan XY, Fu SB, Xia JC et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000; 123: 27-34.
14. Fong Y, Guan X-Y, Guo Y et al. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 2001; 30: 254-60.
15. Rao PH, Arias-Pulido H, Lu XY et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 2004; 4: 5-9.
16. Guan XY, Sham JS, Tang TC et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001; 61: 3806-9.
17. Clement PM, Henderson CA, Jenkins ZA et al. Identification and characterization of eukaryotic initiation factor; 5A:-2. Eur J Biochem 2003; 270: 4254-63.
18. Park MH, Wolff EC, Folk JE. Is hypusine essential for eukaryotic cell proliferation? Trends Biochem Sci 1993; 18: 475-9.
19. Park MH, Wolff EC, Lee YB, Folk JE. Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 1994; 269: 27827-32.
20. Tome ME, Fiser SM, Payne CM, Gerner EW. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 1997; 328: 847-54.
21. Guan XY, Fung JMW, Ma NF et al. eIF-5A2 functions as an oncogene in ovarian carcinogenesis. Cancer Res 2004; 64: 4197-200.
22. Xie D, Ma NF, Pan ZZ et al. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol 2008; 39: 80-6.
23. Marchet A, Mocellin S, Belluco C et al. Gene expression profile of primary gastric cancer: Towards the prediction of lymph node status. Ann Surg Oncol 2007; 14: 1058-64.
24. Xie D, Lau SH, Sham JS et al. Upregulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005; 103: 277-83.
25. Xie D, Sham JS, Zeng WF et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 2005; 36: 777-83.
26. Gospodarowicz MK. Staging of bladder cancer. Semin Surg Oncol 1994; 10: 51-9.
27. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45: 292-6.
28. Hussain SA, James ND. Molecular markers in bladder cancer. Semin Radiat Oncol 2005; 15: 3-9.
29. Kang HA, Hershey JWB. Effect of initiation factor eIF-5A depletion onprotein synthesis and proliferation of Saccharomyces cerevisiae. J Biol Chem 1994; 269: 3934-40.
30. Chen ZP, Chen KY. Marked elevation of hypusine formation activity oneukaryotic initiation factor 5A in v-HA-RAS transformed mouse NIH3T3 cells. Cancer Lett 1997; 115: 235-41.
31. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
32. Clement PM, Johansson HE, Wolff EC, Park MH. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 2006; 273: 1102-14.